phensuximide
Trade name: milontin
Approved
Sep 8, 1953
Phensuximide is an anticonvulsant in the succinimide class. For the treatment of epilepsy. Phensuximide suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in absence (petit mal) seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. Phensuximide's mechanism of action not understood, but may act in inhibitory neuronal systems that are important in the generation of the three per second rhythm. It's effects may be related to its ability to inhibit depolarization-induced accumulation of cyclic AMP and cyclic GMP in brain tissue. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Timeline
1950s
- Sep 8, 1953
Parke-Davis — Earliest FDA Approval
- Sep 8, 1953
Parke-Davis — NDA Organization
Indications
Approved for
Mechanism of action
Approval history
- approvedPriority reviewSep 8, 1953
Chemistry & pharmacology
SMILES
CN1C(=O)CC(C1=O)C2=CC=CC=C2- Mol. weight
- 189.2105 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPhensuximide ↗
- NCATS6WVL9C355G ↗
- ChEMBLCHEMBL797 ↗
Also known as
- fensuccimide
- fensuccimide
- fensuccimide
- fensuximida
- fensuximida
- milontin
- milontin
- milontin
- phensuccimide
- phensuccimide
- phensuccimide
- phensuccimide
- phensuccimide
- phensuccimide
- phensuximid
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide
- phensuximide, (+-)-isomer
- phensuximidum
- phensuximidum
- racemic phensuximide
- rs-phensuximide
- succitimal
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Parke-Davis | For profit | SYN | Sep 8, 1953 |
| Parke-Davis | For profit | NDA | Sep 8, 1953 |